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Abstract 
When the succinate receptor (SUCNR1) is activated in the afferent arterioles of the 
glomerulus it increases renin release and induces hypertension. To study its location in 
other nephron segments and role in kidney function we performed immunohistochemical 
analysis and found that SUCNR1 is located in the luminal membrane of macula densa 
cells of the juxtaglomerular apparatus in close proximity to renin-producing granular 
cells, the cortical thick ascending limb and cortical and inner medullary collecting duct 
cells. In order to study its signaling SUCNR1 was stably expressed in MDCK cells where 
it localized to the apical membrane. Activation of the cells by succinate caused Gq and 
Gi-mediated intracellular calcium mobilization, transient phosphorylation of ERK1/2 and 
the release of arachidonic acid along with prostaglandins E2 and I2. Signaling was 
desensitized without receptor internalization but rapidly re-sensitized upon succinate 
removal. Immunohistochemical evidence of phosphorylated ERK1/2 was found in 
cortical collecting duct cells of wild type but not SUCNR1 knockout streptozotocin-
induced diabetic mice indicating in vivo relevance. Since urinary succinate concentrations 
in health and disease are in the activation range of the SUCNR1, this receptor can sense 
succinate in the luminal fluid. Our study suggests that changes in the luminal succinate 
concentration may regulate several aspects of renal function. 
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Introduction 
G protein-coupled receptors (GPCRs) play a major role in the regulation of many (patho-
)physiological processes in the human body. Their role is to transfer signals from the 
extracellular environment to the inside of the cell via effector proteins and multiple 
cellular signalling pathways. The receptor GPR91[1], which is related to the family of 
P2Y purinoreceptors, was found to be activated by succinate[2] and was therefore 
renamed succinate receptor 1 (SUCNR1). 
Among other organs, SUCNR1 is highly expressed in the kidney[2]. Importantly, there 
are strong indications that the SUCNR1 is involved in hyperglycemia and diabetes-
induced hypertension, because rat and mouse models of hypertension and metabolic 
syndrome have increased succinate levels compared to healthy control animals[3], and 
injection of succinate into normal, but not SUCNR1 knockout, mice induces the 
production and release of renin and hypertension[2]. Also, SUCNR1-mediated renin 
release has been linked to hyperglycemia and diabetes[3;4]. Therefore, the SUCNR1 may 
be an important protein in the kidney-derived onset of hypertension.  
Consistent with its role in renal regulation of volume balance, immunohistochemistry 
identified expression of SUCNR1 near the juxtaglomerular apparatus (JGA), in particular 
the vascular endothelial cells of the afferent arteriole and in the glomerulus. Moreover, 
stimulation of the SUCNR1 in vascular endothelial cells leads to the mobilization of 
intracellular calcium and production of nitric oxide and prostaglandin (PG) E2 release, 
which contribute to the release of renin from granular cells and vasodilation of the 
afferent arteriole[4]. 
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Interestingly, however, SUCNR1 mRNA has also been detected in proximal and distal 
tubules [2], suggesting an additional role for SUCNR1 in the renal tubule. To increase 
our understanding of the function of SUCNR1 in renal physiology, we analyzed the 
expression of SUCNR1 along the nephron, and found that SUCNR1 is also expressed in 
the polarized cells of the thick ascending limb of Henle’s loop (TAL) and the cortical and 
inner medullary collecting duct (CCD and IMCD, respectively). As a model for these 
cells, we subsequently generated SUCNR1-expressing polarized Madin-Darby Canine 
Kidney (MDCK) cells and analyzed the regulation of SUCNR1 and its downstream 
signalling pathways on the (sub)cellular level and in vivo. 
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Results 
Localization of SUCNR1 in the kidney 
To assess whether SUCNR1 may have a role in renal tubular physiology, we set out to 
determine the cellular and subcellular localization of SUCNR1 in the kidney. Staining of 
rat kidney sections for SUCNR1 with antibody Q-15 followed by confocal laser scanning 
microscopy (CLSM) clearly shows that the receptor localizes to the luminal membrane of 
cells morphologically resembling cells of the thick ascending limb (TAL) of Henle’s loop 
(Fig.1A-B). No staining was observed after preabsorption of the antibody with the 
immunizing peptide (not shown). The specificity of this localization was confirmed by 
staining with a second SUCNR1-specific antibody, H-80 (not shown). In addition, 
staining with this antibody reveals expression of SUCNR1 in glomerular cells (Fig.1C-
D), which, as reported[4], likely represent endothelial cells of the glomerular capillaries 
and the afferent arteriole. To assess whether the localization of SUCNR1 is conserved 
between species, labelling of mouse kidneys was performed. Also here, SUCNR1 was 
detected in the luminal membrane of the cortical TAL (supplementary figure S1). 
As SUCNR1 activity is involved in the release of renin from the kidney and considering 
the complex architecture of the JGA, we further assessed whether the cells expressing 
SUCNR1 also express renin, or are in close proximity to renin-expressing cells. Co-
staining of rat kidney sections revealed that in the cortex, the tubular cells expressing 
SUCNR1 do not express renin themselves and that renin is only expressed in granular 
arteriolar cells (Fig.1E-H). SUCNR1-expressing cells in the TAL are often adjacent to 
these renin-expressing cells (Fig.1G-H), suggesting that SUCNR1 is localized to the 
macula densa (MD). To examine this possiblility at a subcellular level, immunogold 
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electron microscopy was performed. As shown in figure 2, SUCNR1 was detected in MD 
cells, both in the apical membrane and in distinct intracellular vesicles morphologically 
resembling endosomes.  
As shown in figure 1I, double immunofluorescence labeling of rat kidney inner medulla 
for SUCNR1 and aquaporin-2 (AQP2), a marker for collecting duct principal cells, 
revealed that SUCNR1 localizes to the IMCD. At high magnification, it is clear that the 
majority of SUCNR1 labeling is associated with the apical plasma membrane domains 
(inset bottom right). The same double labeling performed on the renal cortex (Fig.lJ) 
shows that SUCNR1 is weakly expressed in AQP2-containing cells, indicating that the 
receptor is also expressed in principal cells of the cortical collecting duct (CCD). No 
SUCNR1 staining was found in CCD intercalated cells. In the IMCD, SUCNR1 also 
localizes to the apical membrane, as it does not co-localize with the basolateral 
membrane marker anion exchanger (AE)2 (Fig.1K, inset bottom right and Suppl. 
Fig.S2A), which is especially clear in the later portions of the IMCD (Suppl Fig.S2B). 
Moreover, as shown in Fig.1L, IMCD cells expressing SUCNR1 also express renin. 
Finally, cells of the thin descending limb show weak labeling for SUCNR1 (Suppl. 
Fig.S2B).  
Taken together, these data indicate that the SUCNR1 is, besides endothelial cells of the 
glomerular vasculature, also expressed in the luminal membrane of tubular cells from 
different renal segments where it may be a sensor for succinate in the pro-urine. 
 
Localization of SUCNR1 in MDCK cells 
 5
Since TAL cells and principal cells of the CCD and IMCD are polarized, they may have 
alternative SUCNR1 localization, trafficking and signalling properties compared to non-
polarized, e.g. endothelial, cells[5]. Therefore, we employed Madin-Darby Canine 
Kidney (MDCK) cells as a model to study SUCNR1 localization, signalling and 
regulation. MDCK cells were stably transfected with expression constructs encoding C-
terminally eYFP or c-myc-tagged SUCNR1 and individual clones were isolated. N-
terminal epitope tags could not be used, because these affected the localization of 
SUCNR1 (not shown).  
Based on bioinformatical analysis, the SUCNR1 consists of 7 transmembrane domains, 
which is characteristic for GPCRs, and has two putative N-glycosylation sites: one at 
Asn4 in the N-terminus and one at Asn164 in the second extracellular loop (Fig.3A). 
CLSM analysis of MDCK-SUCNR1-eYFP cells revealed a clear expression in the apical 
domain of the cells, as it showed overlap with staining of apically-applied wheat-germ 
agglutinin, and no co-localization with the basolateral plasma membrane marker E-
Cadherin (Fig.3B). The localization of SUCNR1 in MDCK cells is thus similar to what is 
observed in TAL and CD principal cells in vivo (Fig.1), indicating that the MDCK cell is 
a proper model for MD and principal cells, and that the C-terminal tag does not interfere 
with trafficking of the receptor.  
Western blot analysis of SUCNR1-eYFP cells with GFP antibodies showed a strong 
signal of approximately 90-100 kDa and a weaker doublet of bands of approx. 60 kDa 
(Fig.3C). The upper band of this doublet was absent following digestion with both 
PNGaseF and EndoH, suggesting that the lower and upper band represent the 
unglycosylated and the high-mannose glycosylated immature forms of the receptor, 
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respectively. Upon digestion of the protein mix with PNGaseF, but not endoH, the 90-
100 kDa band completely disappeared into the 60 kDa signal (Fig.3C). This indicates that 
SUCNR1 is only glycosylated at Asn (no O-glycosylation) and that the 90-100 kDa band 
is the N-linked complex-glycosylated form of the receptor. Together, these observations 
reveal that SUCNR1 is expressed as a mature and properly-folded receptor when 
expressed in MDCK cells.  
 
SUCNR1 signalling in MDCK cells. 
To determine the signalling characteristics of the SUCNR1 in polarized cells, we first 
assessed whether this receptor could be activated selectively by succinate. As shown in 
figure 4A, administration of the Emax concentration of 200μM Suc[2] to untransfected 
MDCK cells did not induce phosphorylation of extracellular regulated kinase (ERK1/2), 
whereas these cells showed a robust signal to addition of serum (Fig.4A). In contrast, 
stimulation of MDCK-SUCNR1 cells with succinate for 5 minutes resulted in increased 
phosphorylation of ERK1/2 (Fig.4A), whereas they remained unresponsive to 
administration of a related compound from the Krebs’ cycle, α-ketoglutarate (αKG). 
Activation of the ERK1/2 pathway by GPCRs can be G protein-mediated, which is a 
rapid and transient process (<10 min.), or it can be mediated via β-arrestins, resulting in a 
slower and more sustained phosphorylation of ERK1/2[6;7]. As shown in fig.4B, 
SUCNR1 activation induced transient ERK1/2 phosphorylation, which was at its 
maximum at 2 minutes after addition of ligand and remained significantly increased 
compared to the control at t = 5 and 10 minutes (P<0.05; Student’s T-test), suggesting 
that ERK1/2 activation by this receptors is G protein-mediated. 
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To further investigate receptor signalling, we employed FURA-2 measurements to assess 
receptor-induced intracellular calcium mobilization. SUCNR1-specific activation by 
succinate dose-dependently increased calcium mobilization with a half-maximum 
potency (EC50) of 23.1±12.8μM (Fig.4C). To assess which G proteins were involved in 
the SUCNR1-mediated calcium mobilization, we pre-incubated the cells with 
YM254890, an inhibitor of Gq/11, or pertussis toxin (PTX), an inhibitor of Gi/o. Inhibition 
of Gi resulted in a decrease in the maximum efficacy (Emax), but did not significantly 
affect the potency of the signal (EC50 = 22.1±14.1μM) (Fig.4C). Blockade of the Gq/11 
pathway also resulted in a marked reduction of the maximal efficacy and also resulted in 
a shift of the EC50 to 67.4±14.7μM. Combined application of the blockers resulted in a 
complete absence of calcium mobilization in response to succinate (Fig.4C). These data 
suggest that the SUCNR1 utilizes both the Gq/11 and Gi/o pathways to increase 
intracellular calcium and induce ERK1/2 phosphorylation. 
 
SUCNR1 activation triggers the release of arachidonic acid and the production of 
prostaglandins 
As intracellular calcium mobilization and ERK1/2 phosphorylation can induce the release 
of arachidonic acid (AA)[8], a precursor of prostaglandins, we tested whether activation 
of SUCNR1 was able to induce the release of AA from MDCK cells. As shown in figure 
5A, untransfected control cells did not respond to 200μM Suc, but released [3H]AA could 
be measured after stimulation of endogenous purinoreceptors with 100μM ATP or 
induction of a calcium flux with 1μM of the calcium ionophore ionomycin. In SUCNR1 
cells, however, stimulation with succinate triggered the release of [3H]AA 2.61±0.09 fold 
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over basal levels. This release was not significantly different (P>0.05; One-way Anova) 
from the [3H]AA release measured upon ATP or ionomycin treatment of the SUCNR1 
cells.  
Next, we determined the identity of the prostaglandins released by the SUCNR1 cells 
(Fig.5B). Supernatant collected from unstimulated SUCNR1 cells contained 
prostaglandin (PG)E2, 6-keto-PGF1α (a stable metabolite from PGI2) and PGF2α. 
Stimulation with 200μM succinate significantly (P<0.05) increased PGE2 in both the 
apical and basolateral medium, whereas 6-keto-PGF1α/PGI2 was only increased in the 
apical medium (Fig.5B). In these studies, PFG2α levels remained unaltered (not shown), 
whereas thromboxane (Tx)B2 (a stable metabolite from TxA2) was not detected in the 
supernatant under any of the conditions above. These data indicate that stimulation of 
SUCNR1 in polarized cells increases the release of PGE2 to both sides and of PGI2 to 
only the luminal side. 
 
Desensitization and internalization of the SUCNR1 
To prevent continuous signalling, many GPCRs undergo desensitization and/or 
internalization shortly after agonist stimulation. Calcium mobilization measurements 
showed that pre-treatment of MDCK SUCNR1-eYFP cells with succinate for 15 minutes 
markedly decreased the Emax value (88.6±5.3% reduced) and increased the EC50 value 
(from 26.3μM for control to 88.9μM;Fig.6A), which indicated that the SUCNR1 is 
indeed desensitized. Following desensitization, receptors may either be resensitized, or 
they can be down-regulated. After removal of the ligand, two washes and only a 15 
minute resensitization period at 37ºC, the Emax and EC50 returned to control values 
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(Student’s T-test; P>0.05; Fig.6A). In fact, even agonist pre-treatment for up to 4 hours 
did not affect the rate at which receptor resensitization occurred (data not shown). Similar 
to results of the Fura-2 measurements, pre-treatment of SUCNR1 cells with succinate for 
15 minutes followed by 5 minutes of stimulation with 200μM fresh succinate resulted in 
decreased levels of phosphorylated ERK1/2 to 24.6 ± 7.1% compared to the control cells 
that had not been subjected to succinate pre-treatment (Fig.6B). Pre-treatment as above 
followed by resensitization for 15 minutes at 37ºC and subsequent stimulation with 
succinate for 5 minutes reversed the desensitization effect to a large extent (72.6 ± 8.3% 
compared to control) (Fig.6B), indicating that also SUCNR1-induced ERK1/2 
phosphorylation is subject to desensitization and resensitization.  
To further explore the potential internalization of SUCNR1-eYFP in response to 
succinate, we performed cell surface biotinylation experiments[9-11]. Immunoblot 
analysis revealed that the cell surface (biotinylated) fraction of the mature 90-100 kDa 
form of SUCNR1-eYFP was not reduced by treatment with 200μM succinate for 1 hr at 
37ºC (Fig.6C). This demonstrates that, despite desensitization, SUCNR1 is resistant to 
agonist-induced internalization. In line with this, CLSM analysis of SUCNR1-eYFP cells 
treated as above showed no different subcellular localization compared to untreated 
control cells (Fig.6D). These observations indicate that SUCNR1 undergoes rapid 
desensitization and resensitization, and that the receptor is not subject to agonist-
mediated internalization in polarized MDCK cells. 
 
Signalling of SUCNR1 in the CD of diabetic mice 
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As SUCNR1-mediated pERK1/2 signalling may be involved in the onset of hypertension 
in diabetes, we assessed whether signalling events that occur in our polarized cell model 
can be extrapolated to the in vivo situation. For this, wild-type (SUCNR+/+) and 
SUCNR1 knock-out (SUCRN-/-) mice were made diabetic using streptozotocin, whereas 
control animals were left untreated. As shown in Fig.7A and B, only very few cells in the 
CCD stained positive for pERK1/2 of wild-type and SUCNR1-/- non-diabetic control 
mice. In contrast, the amount of pERK1/2-positive CCD cells in diabetic animals is 
significantly (P<0.05) increased compared to non-diabetic animals. As no pERK1/2 was 
found in the CCD of diabetic SUCNR-/- mice (Fig.7D), the observed increase in 
pERK1/2 levels in the CCD of diabetic mice is likely the consequence of SUCNR1 
activation.  
 
Discussion 
SUCNR1 is expressed in the luminal membrane of the cortical thick ascending limb 
and principal cells of the collecting duct  
Northern blot analysis revealed that the kidney is a major site of expression of the 
succinate receptor SUCNR1[2]. Additionally, analysis of SUCNR1 mRNA expression in 
different nephron segments indicated SUCNR1 expression in the proximal tubule, distal 
nephron and JGA[2]. Indeed, using SUCNR1 specific antibodies, Toma et al. showed 
SUCNR1 expression in endothelial cells of the afferent arteriole and in the glomerulus, 
where it appeared to regulate renin release following detection of blood succinate 
levels[4]. Our data confirm SUCNR1 expression in the glomerular vasculature with 
antibody H-80, likely representing endothelial cells of the glomerular capillaries and the 
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afferent arterioles. Using two different antibodies, however, we also observed SUCNR1 
expression in the luminal membrane of tubular cells of the cTAL, including macula densa 
cells (Figs.1 and 2), of which the latter were located in close proximity to the renin-
producing JGA cells, and in CCD and IMCD principal cells. In the course of our study, 
Vargas et al. also reported SUCNR1 expression and signalling in the MD, as confirmed 
by co-staining with the MD marker nNOS[12]. The possible implications of the 
localization and signalling of the SUCNR1 in cTAL, MD and CD cells is given below.  
 
SUCNR1 signals in response to physiological levels of succinate  
Similar to its localization in renal MD, cTAL and CD principal cells (Fig.1 and 2, Suppl. 
Fig.S1 and S2), epitope-tagged SUCNR1 was expressed in the apical membrane of 
MDCK cells (Fig.3B), suggesting that these cells represent a good model for SUCNR1 
localization and regulation in renal tubular cells. Our data reveal that stimulation of 
SUCNR1 in polarized cells induces the same signaling cascade as found in non-polarized 
cells, as succinate increased intracellular calcium levels via the Gq and the Gi pathway 
and induced ERK1/2 phosphorylation[2]. Moreover, activation of the SUCNR1 induces 
the production and release of PGE2 as observed in vivo[4]. Our MDCK-SUCNR1 cells, 
however, also secrete PGI2, which is only released on the apical side (Fig.5). Whether the 
latter also occurs in vivo and what physiological effect this may lead to remains to be 
established.  
The EC50 value for succinate induced Ca2+ mobilization in MDCK cells (23.1±12.8μM) 
is of the same magnitude as described for non-polarized cells by He et al. (28-68μM)[2] 
and Toma et al. (69μM)[4]. Succinate excretion via the urine in healthy individuals 
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ranges between 2-12 mg/day[13], which, based on a daily urinary output of 1.5 liter, 
corresponds to a urinary succinate concentration between 11 and 67μM. This indicates 
that the urinary succinate levels in healthy individuals are in the physiological range to 
activate the tubular SUCNR1. 
 
SUCNR1 undergoes rapid de- and resensitization at the apical plasma membrane. 
Interestingly, in our MDCK cells, the SUCNR1 undergoes desensitization following 
succinate binding, but is re-sensitized to control levels very quickly following removal of 
succinate (Fig.6). In line with this, the agonists-occupied SUCNR1 is not degraded 
(Fig.6C), and cell surface biotinylation and immunocytochemistry reveal a similar 
membrane localization of the SUCNR1 in untreated control and succinate-treated cells 
(Fig.6C-D). Assuming our MDCK cells mimic SUCNR1 regulation in the cTAL cells, 
the vesicles containing some SUCNR1 in MD cells (Fig.2) may represent recycling 
vesicles, continuously recycling their endocytosed proteins to the plasma membrane.  
Our data are in contrast to those of He et al. who reported succinate-induced 
internalization of the SUCNR1 in HEK293 cells[2]. One possibility is that the SUCNR1 
is regulated differently in non-polarized (HEK293) cells as compared to polarized cells. 
On the other hand, however, the study of He et al. lacks important controls to substantiate 
their conclusion: Fluorescence microscopy is less appropriate to determine plasma 
membrane expression levels compared to cell surface biotinylation assays. Moreover, the 
intracellular expression of the SUCNR1 in cells without succinate stimulation and plasma 
membrane SUCNR1 localization after succinate stimulation were not determined[2]. It 
remains to be established whether the SUCNR1 is internalized in endothelial cells and 
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whether the regulation of the SUCNR1 in MDCK cells mimics that in the polarized 
cTAL/MD/CD cells in vivo. 
 
Putative role of the SUCNR1 in the renal tubule 
Succinate is freely filtered in the glomerulus but is normally reabsorbed in the proximal 
tubules, mainly via sodium-dicarboxylate co-transporters[14]. As such, SUCNR1-
expressing cells of the cTAL, MD and CCD will only sense succinate that fails to be 
reabsorbed in proximal tubules, or that is excreted by or beyond proximal tubule cells. As 
indicated above, however, succinate is found in the urine of healthy individuals at levels 
that will stimulate the SUCNR1[13]. As such, the newly-identified localization of 
SUCNR1 in the luminal membrane of MD, cTAL and CD principal cells may suggest 
several physiological functions for tubular SUCNR1.  
As shown here and as recently described (Fig.1 and [12]), the succinate-induced release 
of PGE2 likely signals to granular cells, which are in close proximity to the basolateral 
side of the MD, to produce and release renin. Considering the known role of the 
glomerular endothelial SUCNR1 in inducing rennin expression and release, and the 
proximal tubular reabsorption of succinate, the tubular SUCNR1 may further increase 
renin production and release only in conditions of hyperglycemia and diabetes when 
filtrated succinate is in excess of reabsorbed levels. 
Besides SUCNR1-mediated release of PGE2 to the basolateral side, tubular activation of 
the SUCNR1 in the cTAL and CD may induce apical release of PGE2/PGI2, as observed 
in our MDCK cells (Fig.5B). As reported for tubular prostaglandins derived from 
cTAL/DCT and CD[15-17], such luminal prostaglandins may reduce blood pressure and 
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hypertension by reducing NaCl reabsorption in the cTAL and diminishing water and/or 
NaCl reabsorption in the DCT and collecting duct. Alternatively, these luminal 
prostaglandins may trigger the release of RAS components from downstream tubular 
cells[18], such as renin from the connecting tubule[19;20] or (pro)renin from the 
collecting duct in diabetes[21], which, via angiotensin II may stimulate sodium retention 
in the collecting duct via the epithelial sodium channel ENaC. However, as the SUCNR1 
and renin are co-expressed in IMCD cells (Fig.1L), SUCNR1 may also directly regulate 
expression and release of renin and/or regulate water- and salt transport in this nehron 
segment. Moreover, SUCNR1-mediated stimulation of ERK1/2 phosphorylation in the 
renal tubules of diabetic mice, as shown in figure 7, is also observed in diabetic 
nephropathy[22], which, in the light of increased renal succinate levels found in diabetic 
animals[4], strongly suggests the involvement of SUCNR1 in this pathological condition.  
Interestingly, previous studies showed that in MD cells, ERK1/2 phosphorylation was 
increasing in time following SUCNR1 stimulation[12], which usually points to the 
presence of pERK1/2 in the cytosol, where it can activate numerous cellular pathways. In 
contrast, in our MDCK cells, which are derived from more distal tubular cells, we found 
a transient rise in ERK1/2 phosphorylation, which is usually associated with migration of 
pERK1/2 to the nucleus and cell proliferation[23]. The physiological impact of this 
discrepancy remains to be elucidated. 
 
Besides the disease conditions indicated above, renal and/or tubular succinate levels may 
also be increased in other pathological states: at low oxygen levels, Krebs’ cycle 
intermediates are converted to succinate[24;25] and, as described for the ischemic retina, 
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SUCNR1 signalling has a major role in the re-oxygenation and repair of the retina by 
stimulating angiogenesis[26]. Hypoxic and ischemic conditions in the kidney are also 
prevalent during organ transplantion, in acute and chronic renal failure, and coincide with 
increased urinary succinate levels[25;27;28], suggesting that tubular SUCNR1 activation 
may play a similar role in the kidney. The exact role of the tubular SUCNR1 in renal 
physiology and disease, however, remains to be established.  
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Materials and Methods 
Expression constructs 
cDNA encoding the human SUCNR1 was a kind gift of Dr. Hampe and Dr. Schaller 
(University of Hamburg, Hamburg, Germany). C-terminal fusions of SUCNR1 with 
enhanced Yellow Fluorescent Protein (eYFP) or the c-myc epitope tag were generated as 
described in the supplementary materials and methods.  
 
Cell culture and cell assays. 
MDCKII cells were maintained as described[29]. Cells were transfected with 2.5μg 
plasmid DNA using Lipofectamine 2000 (Invitrogen, Paisley, UK) and individual clones 
selected and isolated as described[11]. Protein sample preparation and EndoH and 
PNGaseF digestion were performed as described[29]. Cell surface biotinylation 
experiments, ERK1/2 phosphorylation assays, calcium mobilization assays and [3H] 
Arachidonic acid release assays were performed as described in the supplementary 
materials and methods. Samples for prostanoid analysis were prepared as described [30] 
and analyzed as described in the supplementary materials and methods. 
 
Immunoblotting and immunocytochemistry 
Immunoblotting and immunohistochemistry were performed as described in the 
supplementary materials and methods. Primary antibodies used were Rabbit-anti- 
ERK1/2, mouse-anti-phospho-ERK1/2 (Cell Signalling), rat-anti-E-Cadherin and rabbit-
anti-calnexin (Sigma, Poole, UK). Secondary antibodies used were HRP-conjugated 
donkey-anti-goat (Sigma, Poole, UK), goat-anti-rabbit or goat-anti-mouse antibodies (GE 
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Healthcare, Chalfont St. Giles, UK) and Alexa633-conjugated goat-anti-rat, goat-anti- 
rabbit, or Alexa488-coupled goat-anti-rabbit or goat-anti-mouse antibodies (Molecular 
Probes, Eugene, OR).  
 
SUCNR1-/- mice and induction of diabetes. 
All experiments were performed under protocols approved by the Institutional Animal 
Care and Use Committee at University of Southern California. Breeding pairs of 
SUCNR1 -/+ mice (C57BL6 background) were provided by Amgen (Thousand Oaks, 
CA) and bred at University of Southern California. In male SUCNR1-/- mice, or their 
wild-type littermates, diabetes was induced by daily streptozotocin injection for 4 days as 
described [12].  
 
Immunohistochemistry 
Kidney sections were prepared and immunolabeling was performed as previously 
described[4;12;31] and analyzed as described in the supplementary materials and 
methods. Secondary antibodies used were goat-anti-rabbit, Alexa Fluor488; goat-anti-
chicken, Alexa Fluor546; donkey-anti-goat, Alexa Fluor488 (Molecular Probes, 
Invitrogen). Primary antibodies used were rabbit-anti-GPR91(H80), goat-anti-
GPR91(Q15, Santa Cruz), rabbit-anti-GPR91 (Millipore), rabbit anti-GPR91 (Novus 
Biologicals), chicken-anti-renin (kind gift of Hayo Castrup, University of Regensburg, 
Germany), chicken-anti-AQP2, and rabbit-anti-pERK1/2 antibodies (Cell Signaling).  
 
Immunogold electron microscopy.  
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Ultrathin (70nm) cryosections from perfusion fixed rat kidney cortex were prepared and 
analyzed as described in the supplementary materials and methods. Primary antibodies 
were rabbit-anti-GPR91(H80) or goat-anti-GPR91(Q15).  Primary antibodies were 
visualized using goat-anti-rabbit or rabbit-anti-goat antibodies conjugated to 10nm 
colloidal gold particles (BioCell Research Laboratories, UK).  
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Legends and titles 
Figure 1. Renal localization of the SUCNR1  
A) Immunofluorescence labeling using a SUCNR1 antibody (Q-15) identified that 
SUCNR1 is localized to distinct tubule segments. B) Overlay with differential 
interference contrast (DIC) image identifies that SUCNR1 is localized to the cortical 
thick ascending limb of Henle’s loop (TAL). C) Immunofluorescence labeling using an 
alternative SUCNR1 antibody (H-80) localized SUCNR1 to both cells within the 
glomerulus and a region of the TAL associated with the juxtaglomerular apparatus 
(JGA). D) Overlay with DIC image. E) Double immunofluorescence labeling of 
SUCNR1 (Q15) (green) and renin (red) determined that SUCNR1 does not colocalize 
with renin in juxtaglomerular cells. F) Overlay with DIC image. G) Double 
immunofluorescence labeling of SUCNR1 (Q15) (green) and renin (red). H) Overlay 
with DIC image clearly shows that SUCNR1 is detected in tubules morphologically 
resembling the macula densa. I) Double immunofluorescence labeling of renal medulla 
for SUCNR1 (green) and AQP2 (red) determined that SUCNR1 localizes to the IMCD. 
At high magnification (inset bottom right), it is clear that the majority of SUCNR1 
labeling is associated with the apical plasma membrane domains. J) Double 
immunofluorescence labeling of SUCNR1 (green) and AQP2 (red) in the cortex, where 
SUCNR1 is very weakly expressed in AQP2 containing tubules. K) In the IMCD, 
SUCNR1 (green) does not colocalize with the basolateral membrane marker AE2 (red). 
L) In the IMCD, SUCNR1 (green) can be observed in renin-expressing cells (red). 
Abbreviations; G = glomerulus, T = thick ascending limb, P = proximal tubule, A = 
arteriole, MD = macula densa.  
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 Figure 2. Immunoelectron microscopy of SUCNR1 in rat kidney.  
A) Overview of the macula densa (MD) region of the thick ascending limb. B) In the MD 
cells immunogold labeling of SUCNR1 (H80) is observed intracellularly (arrowheads) 
and in the apical plasma membrane domains (inset, arrows). C) Using an alternative 
SUCNR1 antibody (Q15), a similar pattern of labeling is observed, with gold particles in 
direct contact with the plasma membrane (inset). D) In some MD cells, very few gold 
particles are observed in the plasma membrane. In these cells, labeling of distinct vesicles 
morphologically resembling endosomes (*) are apparent. Abbreviations; PT = proximal 
tubule, MD = macula densa, EM = extraglomerular mesangium, apm = apical plasma 
membrane, lm = lateral membrane. 
 
Figure 3. Subcellular localization and glycosylation state of SUCNR1 in MDCK cells 
A. Topology of the SUCNR1: The structure of GPCRs is composed of 7 transmembrane 
domains, indicated in roman numbers. Using bioinformatic tools on the amino acid 
sequences of SUCNR1, we predicted the topology of the receptor and the location of its 
potential N-glycosylation sites. 
B. Subcellular localization of the SUCNR1: MDCK-SUCNR1-eYFP cells were seeded 
on filters, grown to confluence and labelled with the plasma membrane markers E-
Cadherin (basolateral membrane) or wheat germ agglutinin (WGA; apical membrane) 
followed by CLSM analysis. Shown are representative XY scans and a corresponding 
cross-section.  
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C. Glycosylation state of the SUCNR1: MDCK-SUCNR1-eYFP cells were lysed, left 
untreated (control), or digested with endoH or PNGaseF (indicated). Samples were 
analyzed by SDS-PAGE and subjected to immunoblotting using a sheep-anti-GFP 
antiserum. 
 
Figure 4. ERK1/2 and Calcium signalling by the SUCNR1 
A. Ligand specificity of SUCNR1 signalling: Untransfected MDCK cells or SUCNR1-
eYFP cells were grown to confluence and starved overnight and for a subsequent period 
of two hours. Next, cells were incubated with vehicle (control), 200μM succinate or αKG 
(indicated) for 5 minutes at 37ºC, followed by termination of the reaction on ice. 
Subsequently, cells were lysed and analyzed by SDS-PAGE followed by immunoblotting 
using anti-total ERK1/2 or anti-phospho-ERK1/2 antibodies. Signals were quantified 
using densitometry and are represented as fold increase over control (n=3). 
B. Time-dependent ERK1/2 phosphorylation: MDCK-SUCNR1-eYFP cells were grown 
and starved as in A and subsequently incubated with 200μM succinate for the indicated 
times. Next, cells were cooled on ice and cell lysates analyzed and quantified as 
described under A (n=3). 
C. Calcium signalling and G protein coupling of the SUCNR1: MDCK-SUCNR1-eYPF 
cells were seeded in 96 multiwell plates, left untreated (control), treated overnight with 
the Gi/o inhibitor PTX, 2 hrs with the Gq/11 inhibitor YM254890, or a combination of both 
and subsequently loaded with FURA-2 AM. Cells were challenged with increasing 
concentrations of agonist and calcium mobilization was measured as changes in the λ340/ 
λ380 ratio using a FLEX-station. Pooled data of three individual experiments is shown.  
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 Figure 5. Activation of SUCNR1 triggers the release of arachidonic acid and the 
production of prostaglandins 
A. Measurement of Arichadonic Acid release: Untransfected control cells, MDCK-
SUCNR1-eYFP cells were seeded in 24 MW plates, starved and loaded 
with[3H]Arachidonic acid (AA). Subsequently, cells were treated with 200μM Suc, 
100μM ATP or 1μM ionomycin (indicated) for 15 minutes at 37ºC. Subsequently, 
released[3H]AA was measured by counting the supernatant in a scintillation counter. 
Cells were lysed and total lysates were counted to determine total[3H]AA incorporation 
into the cells. The graph shows the percentage[3H]AA that was released. Bars indicated 
with an asterisk are significantly different from the untreated controls (P<0.05; n=3).  
B. Production and release of prostaglandins: MDCK-SUCNR1-eYFP cells were seeded 
on filters and grown to confluence. Subsequently, cells were left untreated (control) or 
treated with 200μM succinate or 100μM ATP for 6 hrs at 37ºC. Subsequently, the apical 
(white bars) and basolateral (black bars) culture medium was removed from the cells and 
analysed for levels of prostaglandin E2, prostacyclin I2, and/or their metabolites. 
Asterisks indicate significantly (P<0.05; n=3) increased levels compared to their 
respective controls. 
 
Figure 6. Desensitization and resensitization of the SUCNR1 
A. Calcium measurements: MDCK-SUCNR1-eYFP cells were seeded in 96 MW plates 
and were left untreated (■), pretreated with 200μM succinate for 15 minutes (▲), 
followed by ligand removal and resensitization for 15 minutes (▼). Cells were then 
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challenged with increasing concentrations of agonist and calcium mobilization was 
measured and analyzed as described in the legend to figure 4. Pooled data of 3 
independent experiments is shown. 
B. ERK1/2 phosphorylation: MDCK-SUCNR1-eYFP cells were pre-treated with 
succinate as above, and subsequently challenged for 5 minutes with 200μM Suc. Cells 
were then placed on ice, washed twice with ice-cold PBS-CM, lysed in sample buffer and 
analysed for phosphorylated (P) or total ERK1/2 levels by immunoblotting as described 
in the legend to fig.4. (n=3) 
C. Plasma membrane localization of the SUCNR1: MDCK-SUCNR1-eYFP cells were 
seeded on filters and grown to confluence. Subsequently, cells were left untreated 
(control) or treated with 200μM succinate for 1 hr at 37ºC. Cells were rapidly cooled on 
ice, subjected to apical cell surface biotinylation and samples were analyzed by SDS-
PAGE followed by immunoblotting using anti-GFP antibodies. A representative blot is 
shown. Immunoblot signals for the cell-surface fraction of succinate-treated and 
untreated control cells were quantified using densitometry and were found to be not 
significantly different. (P>0.05; n=3) TL; Total lysates, Biot.; Biotinylated cell-surface 
fraction.   
D. Subcellular localization of the SUCNR1: MDCK-SUCNR1-eYFP cells were grown 
and pre-treated as described under C. Subsequently, cells were fixed and analyzed by 
CLSM. Shown are representative XY scans (n=4) and a corresponding cross-section. 
 
Figure 7. Immunolocalization of pERK1/2 in control and diabetic kidney 
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(A-D) Representative images of pERK1/2 immunofluorescence (red) in control non-
diabetic SUCNR1+/+ (A), SUCNR1-/- (B), and diabetic SUCNR+/+ (C), GPR91 -/- (D) 
kidneys. (E) Summary of pERK1/2 in control non-diabetic (C) and diabetic (DM) kidney 
sections based on the number of pERK1/2-positive distol nephron cells per field. Error 
bars represent SEM. *: P<0.05 DM SUCNR1 GPR91 +/+ vs. DM SUCNR1-/-, #:P<0.05 
vs DM SUCNR1+/+ (n=6). CNT: connecting segment, CCD: cortical collecting duct. 
Nuclei are stained blue. Scale bar is 20μm.  
 
Supplemental Figure 1. Localization of SUCNR1 in mouse and rat kidney. A) 
Immunoperoxidase labeling using a SUCNR1 goat polyclonal antibody (Q-15) identified 
that SUCNR1 is localized to the TAL associated with the juxtaglomerular apparatus 
(JGA). B) Labeling using an alternative SUCNR1 rabbit polyclonal antibody (H-80) 
confirmed SUCNR1 expression in some TALs. C) SUCNR1 labeling is associated with 
the apical plasma membrane of the TAL. Abbreviations; G = glomerulus, T = thick 
ascending limb  
 
Supplemental Figure 2: Localization of SUCNR1 in rat kidney IMCD. A) 
Immunoperoxidase labeling demonstrates that SUCNR1 is expressed in the IMCD. B) In 
the later portions of the IMCD (IMCD2/3), SUCNR1 labeling is associated with the 
apical plasma membrane. Abbreviations; IMCD = inner medullary collecting duct. 
 
 
 
 Supplementary Materials and Methods 
Expression constructs 
cDNA encoding the human SUCNR1 was a kind gift of Dr. Hampe and Dr. Schaller 
(University of Hamburg, Hamburg, Germany). To generate C-terminal fusions of each 
receptor with enhanced Yellow Fluorescent Protein (eYFP) or the c-myc epitope tag, this 
cDNA was used in the polymerase chain reaction with the sense primer 91FWD 
(5’GAAGCTTGCCACCATGGCATGGAATGCAACTTG3’) to introduce a restriction 
site and the Kozak sequence (indicated in bold) upstream of the ATG start codon. To 
introduce a KpnI restriction site (indicated in bold) over the stop codon for fusion with 
eYFP, the antisense primer 91insKpnI 
(5’CAGGTACCCTTTTCTCTGAATGAAAGTAG3’) was employed. For fusion of the 
C-terminal c-myc tag, a combination of 91FWD with 91myc 
(5’CACTGATGAGCTTCTGTTCCTTTTCTCTGAATG3’) was used. Subsequently, the 
product was subjected to a second round of PCR using 91FWD in combination with 
5’CTGCGGCCGCTACAGGTCCTCTTCACTGATGAGCTTCTG3’ to fuse a NotI site 
to the c-myc tag. All PCR products were cloned into their corresponding restriction sites 
of the pEYFP-NI vector and their sequences verified.  
 
Cell culture and transfection 
MDCKII cells were maintained as described[1]. Cells were transfected with 2.5 μg 
plasmid DNA using Lipofectamine 2000 (Invitrogen, Paisley, UK) and individual clones 
selected and isolated as described[2]. Protein sample preparation and EndoH and 
PNGaseF digestion were performed as described[1]. 
 
ERK1/2 assay 
MDCK cells were seeded in 12 multiwell (MW) Costar plates at a density of 200,000 
cells/cm2 and grown to confluence. Subsequently, cells were starved overnight in serum-
free culture medium, and the medium was replaced the next morning for an additional 2 
hour starvation period. When the Gi/o inhibitor Pertussis toxin (PTX, 25 ng/ml, Sigma, 
Poole, UK) was used, it was present throughout the starvation period, whereas the Gq/11 
inhibitor YM-254890[3] was present during the final 2 hours of serum starvation. Next, 
cells were stimulated with the published Emax concentration[4] of 200 μM succinate 
(Sigma, Poole, UK) for the indicated time periods, followed by immediate cooling on ice 
and 2 washes with ice-cold PBS with 1mM MgCl2 and 0.1mM CaCl2 (PBS-CM). Cells 
were lysed in Laemmli buffer with 0.1 M dithiothreitol (DTT) and analyzed by 
immunoblotting followed by densitometry of the signals. 
 
Cell surface biotinylation 
Cells were grown on 6MW costar filters to confluence. Cells were left untreated or 
treated with succinate for 60 minutes followed by rapid cooling on ice and two washes 
with ice-cold PBS-CM. Cells were then subjected to cell surface biotinylation as 
described[2] 
 
SDS-PAGE and immunoblotting 
Protein samples were analyzed on 4-12% Novex gels (Invitrogen, Paisley, UK), and 
immublotted using an in-house generated sheep-anti GFP antiserum, or rabbit-anti c-myc 
antibodies (Cell Signalling, Hitchin, UK). Rabbit-anti ERK1/2 and mouse-anti phospho-
ERK1/2 antibodies were from Cell Signalling. As secondary antibodies, HRP-conjugated 
donkey-anti goat (Sigma, Poole, UK), goat-anti rabbit or goat-anti mouse antibodies (GE 
Healthcare, Chalfont St. Giles, UK) were used. Detection was performed using Westpico 
Chemiluminescence substrate (Thermo Scientific).  
 
Immunocytochemistry 
Immunocytochemistry and confocal laser scanning microscopy (CLSM) of MDCKII 
cells was performed as described[1;5]. Primary antibodies used were rat-anti E-Cadherin, 
rabbit-anti calnexin (Sigma, Poole, UK), mouse-anti c-myc, rabbit-anti c-myc (Cell 
Signaling Technology, Hitchin, UK). Secondary antibodies used were Alexa633-
conjugated goat-anti rat, goat-anti rabbit, or Alexa488-coupled goat-anti rabbit or goat-anti 
mouse (Molecular Probes, Eugene, OR). 
 
Calcium mobilization assay 
Cells were seeded in black-walled, clear-bottomed 96 MW plates at a density of 30,000 
cells/well, grown overnight and subsequently loaded with 3 μg/ml FURA-2-AM (Sigma, 
Poole, UK) for 1 hour. Cells were washed three times in HEPES-glucose buffer (130 mM 
NaCl, 5 mM KCl, 20 mM HEPES, 10 mM D-glucose, 1 mM MgCl2, 1 mM CaCl2 (pH = 
7.2) and allowed to equilibrate in 100 μl buffer for 15 min. at room temperature. Cells 
were transferred to a FLEXstation (Molecular Devices) and using the FLEXstation’s 
internal pipetting robot, 100 μl of two-times concentrated succinate was added to each 
well to stimulate the cells. Every three seconds λ=340/λ=380 ratios were measured for a 
total time period of 3 min. The difference between the maximum and minimum ratio 
measured over this period was used as readout for cytosolic calcium mobilization. 
Samples were measured in quadruplicate and experiments were performed at least in 
threefold, of which pooled data is presented. The data is shown as a relative increase 
compared to the negative control (no ligand).  
 
Immunohistochemistry 
Kidney sections were prepared and immunolabeling was performed as previously 
described[6-8]. For confocal laser scanning microscopy studies, the following secondary 
fluorescent antibodies were used at a 1:1,000 dilution: goat anti-rabbit IgG, Alexa Fluor 
488; goat anti-chicken IgG, Alexa Fluor 546; donkey anti-goat IgG, Alexa Fluor 488 
(Molecular Probes, Invitrogen). Laser confocal microscopy was carried out with a Leica 
TCS-SP2 laser confocal microscope. For immunoperoxidase labeling, staining was 
detected using a horseradish peroxidase-conjugated secondary antibodies (Dako) and 
visualized with 0.05% 3,3'-diaminobenzidine tetrachloride (DAB, Kemen Tek, 
Copenhagen, Denmark). Light microscopy was carried out with a Leica DMRE (Leica 
Microsystems). Antibodies used were rabbit anti-GPR91(H80, Santa Cruz) at 1:250 
dilution, goat anti-GPR91 (Q15, Santa Cruz) at 1:200 dilution, rabbit anti-GPR91 
(Millipore) used at 1:1000 dilution, rabbit anti-GPR91 (Novus Biologicals, Littleton, CO)  
chicken anti-renin antibody (a kind gift of Hayo Castrup, University of Regensburg, 
Germany), a chicken anti-AQP2 antibody, and rabbit anti-pERK1/2 (Cell Signaling 
Technology).  
 
Immunogold electron microscopy.  
Ultrathin (70nm) cryosections from perfusion fixed rat kidney cortex were prepared on a 
Reichert Ultracut S cryo-ultramicrotome (Leica). Cryosections were blocked by 
incubation in PBS containing 0.05 M glycine and 0.1% skim milk powder and 
subsequently incubated overnight at 4°C with rabbit anti-GPR91(H80, Santa Cruz) at 
1:150 dilution or goat anti-GPR91 (Q15, Santa Cruz) at 1:100 dilution in PBS containing 
0.1% skim milk powder. The primary antibody was visualized using goat anti-rabbit IgG 
or rabbit anti-goat IgG conjugated to 10-nm colloidal gold particles (BioCell Research 
Laboratories, UK), diluted 1:50 in PBS with 0.1% skim milk powder and 
polyethyleneglycol (5 mg/ml). The cryosections were stained with 0.3% uranyl acetate in 
1.8% methyl-cellulose for 6 min before examination in a FEI Morgagni electron 
microscope.  
 
[3H]Arachidonic acid release 
Cells were seeded in 24 MW plates at a density of 100,000 cells/cm2 and grown for 24 
hours. Next, cells were loaded overnight with 0.25 μCi [3H]arachidonic acid (AA, GE 
Healthcare, Chalfont St. Giles, UK) in starvation medium. Next, cells were washed 3X in 
HEPES-glucose buffer supplemented with 0.05% BSA followed by stimulation with 250 
μl HEPES-glucose-BSA buffer with 200 μM agonist for 15 minutes at 37ºC. The reaction 
was stopped by placing the cells on ice. The buffer was removed and counted in a 
scintillation counter. To determine total incorporation of [3H]AA, the cells were lysed in 
250 μl HEPES-glucose buffer with 0.5% Triton-X100 and the lysate counted in a 
scintillation counter. Data is represented as (released/total)*100%. 
 
Prostanoid analysis 
Samples were prepared as described[9] with minor modifications. MDCK cells were 
incubated with ligands for 6 hours and apical or basolateral supernatants collected. 
Subsequently, the supernatants were spiked with ~1 ng of deuterated internal standards, 
and the solvent was removed. The methoxime was obtained through reaction with an O-
methylhydroxylamine hydrochloride-acetate buffer. After acidification to pH 3.5, 
prostanoid derivatives were extracted, and the pentafluorobenzylesters were formed. 
Samples were purified by thin layer chromatography, and a broad zone with RF 0.03-0.4 
was eluted. After withdrawal of the organic layer, trimethylsilyl ethers were prepared by 
reaction with bis(trimethylsilyl)-trifluoroacetamide and thereafter subjected to 
GC/MS/MS analysis on a Finnigan MAT TSQ700 GC/MS/MS (Thermo Electron Corp., 
Dreieich, Germany) equipped with a Varian 3400 gas chromatograph (Palo Alto, CA) 
and a CTC A200S autosampler (CTC Analytics, Zwingen, Switzerland). 
 
Glycosylation motifs, transmembrane domain and topology predictions 
The protein sequence for SUCNR1 (Acc. NP_149039) was analyzed using the 
transmembrane and N-glycosylation prediction tools available at the PredictProtein[10] 
website (www.predictprotein.org). 
 
Statistical analysis 
All quantified data were measured as triplicate samples, unless indicated otherwise, and 
experiments were performed at least in threefold. Statistical analysis was performed using 
the one-way Anova or the Student’s T-test as indicated. P-values<0.05 were considered 
significant. 
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